PPY-988 is a gene therapy commercialized by Novartis, with a leading Phase II program in Dry (Atrophic) Macular Degeneration. According to Globaldata, it is involved in 4 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PPY-988’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PPY-988 is expected to reach an annual total of $2 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GT-005 is under development for the treatment of geographic atrophy secondary to dry age related macular degeneration. The therapeutic candidate is administered by subretinal route as an injection. The drug candidate is a recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor, which acts by targeting complement factor I (CFI) gene.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% over FY2021. The operating profit of the company was US$9,197 million in FY2022, compared to an operating profit of US$11,689 million in FY2021. The net profit of the company was US$6,955 million in FY2022, compared to a net profit of US$24,021 million in FY2021.
For a complete picture of PPY-988’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.